扩大战略合作！药明生物赋能Arcus Biosciences研发同类最优抗肿瘤CD39抗体

中国, 上海

美国，加利福尼亚州海沃德

2020年12月10日

全球领先的开放式生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）与专注肿瘤领域的生物制药公司Arcus Biosciences（以下简称Arcus，纽交所股票代码：RCUS）今日宣布扩大双方战略合作伙伴关系。根据协议，Arcus公司将借助药明生物一体化技术平台研发抗CD39抗体，并拥有相关抗体产品的全球独家开发和商业化权益。这也是药明生物赋能Arcus公司开发的第四个抗体项目。

研究发现，ATP-腺苷通路在肿瘤微环境免疫抑制反应中发挥了关键作用。阻断一个或多个关键靶点（CD39、CD73或A2a和A2b腺苷受体）可以减少免疫抑制性腺苷的生成或降低其活性，从而激活肿瘤免疫效应。此外，CD39抑制剂还有助于增加肿瘤细胞内的ATP，而此类ATP对于树突状细胞的激活和聚集具有重要作用。临床前实验表明，CD39抑制剂联用CD73抑制剂或其他腺苷受体抑制剂，可有效抑制腺苷通路，增强肿瘤免疫效应。

作为一家聚焦肿瘤领域的生物制药公司，Arcus Biosciences利用其深厚的跨学科专业知识发现高度差异化的疗法，并广泛开发新型联合疗法，以解决尚未满足的临床需求。Arcus目前有4个处于临床开发阶段的分子：Etrumadenant（AB928），是目前首个也是唯一一个处于临床阶段的双重A2a/A2b腺苷受体拮抗剂，目前正在进行多项Ⅰb和Ⅱ期临床试验，用于治疗前列腺癌、结直肠癌、非小细胞肺、胰腺癌和三阴性乳腺癌等多种适应症。AB680是首个处于临床阶段的小分子CD73抑制剂，目前正在进行Ⅰ期临床试验，联合zimberelimab和吉西他滨/蛋白结合型紫杉醇用于转移性胰腺癌一线治疗。Domvanalimab（AB154）是一种抗TIGIT单克隆抗体，也是一种潜在的新型肿瘤免疫骨干疗法，目前正在进行一项三臂随机Ⅱ期临床试验，评估zimberelimab单药疗法，zimberelimab与AB154的联合疗法，zimberelimab、AB154及AB928的三药联合疗法用于PD-L1高表达的转移性非小细胞肺癌一线治疗。Zimberelimab（AB122）是一款抗PD-1抗体，目前正在进行Ⅰb期临床试验，评估单药疗法用于治疗未有PD-1疗法获批的癌症适应症，以及多药联合疗法的治疗潜力。如需更多信息，请访问：www.arcusbio.com。

药明生物（股票代码：2269.HK）作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。截至2020年6月30日，在药明生物平台上研发的综合项目达286个，包括141个处于临床前研究阶段，125个在临床早期（I期，II期）阶段，19个在后期临床（III期）以及1个在商业化生产阶段。预计到2023年后，公司在中国、爱尔兰、美国、德国和新加坡规划的生物制药生产基地合计产能将超过28万升，这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。如需更多信息，请访问：www.wuxibiologics.com。

SHANGHAI and HAYWARD, CA

December 10, 2020 

WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, and Arcus Biosciences, Inc. (Arcus) (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced an expansion of their existing strategic relationship under which the parties will discover anti-CD39 antibodies using WuXi Bio's proprietary technology. This CD39 collaboration represents the fourth antibody development program on which the two companies have joined forces. Arcus was granted exclusive worldwide rights to anti-CD39 antibodies discovered under the collaboration and will be responsible for all further development and commercialization activities of such anti-CD39 antibodies.

The ATP-adenosine axis is believed to play a critical role in maintaining an immunosuppressed tumor microenvironment. Inhibition of one or more of the key nodes (CD39, CD73, or adenosine A2a and A2b receptors) along this axis aims to reduce the formation or activity of the highly immunosuppressive adenosine. A potential additional benefit of CD39 inhibition, aside from blocking an important source of adenosine, is the increase in intra-tumoral ATP, an important molecule for the recruitment and activation of dendritic cells. Preclinical experiments indicate that the combination of CD39 inhibition with either CD73 or adenosine receptor inhibition provides robust inhibition of this axis and increased anti-tumor immunity.

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer evaluating zimberelimab monotherapy, AB154 with zimberelimab and AB154 plus AB928 with zimberelimab. Zimberelimab (AB122), Arcus's anti-PD-1 monoclonal antibody, is also being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD-1 treatment options, and in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients. As of June 30, 2020, there were a total of 286 integrated projects, including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.